In 2024, Albert Bourla earned $9.82M in total compensation at Pfizer, including $1.80M salary and $7.02M bonus. Most recently sold 132,508 shares in Nov 2020. Currently holds stock worth $9.45M. 6+ years at the helm of Pfizer.
Compensation History
Annual executive compensation data for Albert Bourla, including salary, bonuses, and stock awards.
Year
2024
Total Compensation
$9.82M
Salary
$1.80M
Bonus
$7.02M
Other
$996.06K
Salary
$1.80MBoard Justification
Pfizer’s executive compensation program is consistent with the goals of its executive compensation philosophy to align pay and performance and increase shareholder value.
Bonus
$7.02MBoard Justification
Annual incentive awards, earned under the GPP for the performance year noted and paid to the NEO early in the following year.
Other Compensation
$996.06KBoard Justification
Includes Aircraft Usage, Financial Counseling, Car Usage, Security, Savings Plan, and Supplemental Savings Plan.
Restricted Stock
Board Justification
N/A
Performance Metrics
Adjusted Net Income, Total Revenue, Adjusted Diluted EPS, Cash Flow from Operations
Albert Bourla
CEO of Pfizer
Education
Doctor of Veterinary Medicine (DVM) from the Veterinary School of Aristotle University of Thessaloniki, Greece
Field of Expertise
Healthcare & Life Sciences - Pharmaceuticals
Sector of Economy
Healthcare
Born
October 21, 1961 - 64 years ago
CEO of Pfizer for
6 years 11 months (Jan 2019 - Present)
Previous Experience
Group President, Pfizer Innovative Health, Group President, Global Innovative Pharma Business, President and General Manager of the Established Products Business Unit.
Other Pfizer CEOs
Holdings
Track Albert Bourla's stock holdings and portfolio value over time.
Total Stock Sold
$5.75M
$5.75M
150,898 PFE shares
What if they kept their stock?
If Albert Bourla didn't sell their stock, today they would have:
Extra PFE150,898 shares worth $3.88M.
This is -32.51% and $1.87M less than what they got when they sold the stock.
Insider Trading
Albert Bourla's recent stock transactions, purchases, and sales filed with the SEC.
$5.56M
PFE at $41.94/share
Nov 9, 2020
Sale
96,183 shares
PFE
Feb 27, 2019
Received
12,891 shares
PFE
Feb 27, 2017
Received
$552.53K
PFE at $30.05/share
Nov 4, 2016
Sale
3,732 shares
PFE
Feb 28, 2016
Received
4,474 shares
PFE
Feb 25, 2015
Received
21,140 shares
PFE
Feb 26, 2014
Received
Rivals
Compare Albert Bourla with competitor CEOs and industry peers.
Daniel O'Day
CEO of Gilead Sciences
2024 Compensation
Stock
$18.79M
Salary
$1.77M
Bonus
$0.00
Other
$1.34M
Total Holdings
$23.48M
Robert M. Davis
CEO of Merck & Co.
2024 Compensation
Stock
$18.10M
Salary
$1.62M
Bonus
$0.00
Other
$561.11K
Total Holdings
$43.45M
Stanley C. Erck
CEO of Novavax
2023 Compensation
Stock
$129.78K
Salary
$50.90K
Bonus
$0.00
Other
$3.83M
Total Holdings
$4.60M
Joaquin Duato
CEO of Johnson & Johnson
2024 Compensation
Stock
$7.13M
Salary
$1.60M
Bonus
$3.22M
Other
$1.08M
Total Holdings
$1.09M
Stéphane Bancel
CEO of Moderna
2023 Compensation
Stock
$0.00
Salary
$1.58M
Bonus
$1.91M
Other
$1.07M
Total Holdings
$335.71M
Christopher Boerner
CEO of Bristol-Myers Squibb
2023 Compensation
Stock
$0.00
Salary
$1.50M
Bonus
$0.00
Other
$311.64K
Total Holdings
$7.39M